Tyra Biosciences (TYRA) Net Equity Issued and Repurchased (2021 - 2026)
Tyra Biosciences' (TYRA) quarterly Net Equity Issued and Repurchased came in at $147.9 million in Q1 2026, up 278.93% on a QoQ basis from -$82.6 million in Q3 2021.
Powered by 
Analysis
Tyra Biosciences (TYRA) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $147.9 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $147.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147.9 million (changed N/A YoY) and the FY2021 annual result came in at $23.5 million, up 0.79% from the prior year.
- Net Equity Issued and Repurchased improved to $147.9 million in Q1 2026, from -$82.6 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $147.9 million in Q1 2026 to a low of $147.9 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Tyra Biosciences | 1.93 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 147.85 Mn |
| Jun 30, 2021 | 28,000.00 |
| Mar 31, 2021 | 106.10 Mn |